Decoy Therapeutics Inc. (DCOY): Nasdaq/NYSE listing notice — Salarius Pharma gets Nasdaq extension to Sep 3 for bid price compliance; will pursue reverse split if needed

Decoy Therapeutics Inc.

Nasdaq granted Salarius until Sep 3, 2024 to regain $1.00 minimum bid price compliance.
Bid price must close at or above $1.00 for 10 consecutive business days by September 3.
Company notified Nasdaq it will seek a reverse stock split if necessary to meet the requirement.
Failure to regain compliance by Sep 3 could lead to delisting notice and appeal process.
September 2023 non-compliance letter gave until March 4, 2024; extension now granted.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Decoy Therapeutics Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

int the Company would have an opportunity to appeal the delisting determination to a Nasdaq Listing Qualifications Panel (the “Panel”), but there can be no assurance that the Panel would grant the Company’s request for continued listing. As a condition of the Approval imposed by Nasdaq Listing Rule 5810(c)(3)(a), the Company notified Nasdaq that it would seek to implement a reverse stock split, if necessary, to regain compliance with the Bid Price Rule. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its

View on SEC.gov

6 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Decoy Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001615219-24-000019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.